患有充血性心力衰竭的ICU患者早期使用美托普罗罗尔与30天死亡率的增加有关:一种因果机器学习研究
1Zunyi Fourth People's Hospital, Zunyi, Guizhou, China.
Frontiers in pharmacology
|February 25, 2026
概括
早期在重症监护室 (ICU) 治疗充血性心力衰竭 (CHF) 患者的美托普罗洛的使用可能会增加30天死亡率. 高风险患者的不良反应明显,建议在早期服用时谨慎行事.
科学领域:
- 心脏病学 心脏病学
- 关键护理医学 关键护理医学
- 药理学 药理学是指药理学的学科.
背景情况:
- 在重症监护室 (ICU) 住院的重症结合性心力衰竭 (CHF) 患者中使用美托普罗罗尔具有有争议的风险效益概况.
- 高质量的因果证据关于在这个人群中早期给予美托普罗罗尔的证据有限.
研究的目的:
- 通过使用现实世界的数据,研究早期使用美托普罗罗尔对ICU中心血管疾病患者30天死亡率的平均治疗效应 (ATE).
- 探索个体治疗效应 (ITE) 的异质性,以确定与不同治疗反应相关的患者特征.
主要方法:
- 使用MIMIC-IV数据库查看患者数据和临床特征.
- 员工倾向性得分匹配 (PSM) 以平衡基线混因素.
- 应用因果森林模型来估计ATE和ITE,包括条件平均处理效应 (CATE) 和基于ITE的四分位数分析.
主要成果:
- 早期使用美托普罗罗尔与30天ICU死亡率增加2%有关 (ATE = 0.02).
- 影响ATE的关键变量包括APSIII,年龄和SOFA分数.
- 个体治疗效果各不相同,在高APSIII,晚年,高SOFA,高白细胞计数和高血尿素的患者中观察到更高的死亡风险.
结论:
- 早期 (在24小时内) 对患有心血管疾病的ICU患者给予美托普罗罗尔与30天死亡率的增加有关.
- 治疗效果异质,高风险患者小组的结果明显较差.
- 由于潜在的不良影响,在高风险的CHF患者中,需要仔细考虑早期使用metoprolol.
相关概念视频
01:30Heart Failure IV: Classification and Diagnostic Evaluation
476
Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
476
01:30Heart Failure V: Medical Management
400
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
400
01:26Heart Failure Drugs: Inotropic Agents
1.6K
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
1.6K
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
1.3K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.3K
01:22Heart Failure Drugs: β-Blockers
1.0K
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
1.0K
01:28Acute Coronary Syndrome IV: Interprofessional Care
337
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
337